Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia

References

• AlbaneseABhatiaKBressmanSBPhenomenology and classification of dystonia: a consensus updateMov Disord201328786387323649720
   PubMed Web of Science ®Google Scholar
• National Institutes of HealthThe DystoniasNIH Publication 12 7172012 Available from: http://www.ninds.nih.gov/disorders/dystonias/dystonias_brochure_508comp.pdfAccessed December 18, 2015
   Google Scholar
• MordinMMasaquelCAbbottCCopley-MerrimanCFactors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled studyBMJ Open2014410e005150
   Web of Science ®Google Scholar
• PekmezovicTSvetelMIvanovicNQuality of life in patients with focal dystoniaClin Neurol Neurosurg2009111216116418995953
   PubMed Web of Science ®Google Scholar
• SlawekJFriedmanAPotulskaAFactors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injectionsFunct Neurol20072229510017637212
   PubMed Web of Science ®Google Scholar
• MolhoESAgarwalNReganKHigginsDSFactorSAEffect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment statusMov Disord20092491384138719441129
   PubMed Web of Science ®Google Scholar
• AlbaneseAAsmusFBhatiaKPEFNS guidelines on diagnosis and treatment of primary dystoniasEur J Neurol201118151820482602
   PubMed Web of Science ®Google Scholar
• NovakICampbellLBoyceMFungVSBotulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statementEur J Neurol201017Suppl 29410820633181
   PubMed Web of Science ®Google Scholar
• SimpsonDMBlitzerABrashearAAssessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology200870191699170618458230
   PubMed Web of Science ®Google Scholar
• ComellaCLJankovicJTruongDDHanschmannAGrafe S;US.XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystoniaJ Neurol Sci20113081–210310921764407
   PubMed Web of Science ®Google Scholar
• GreenePKangUFahnSBrinMMoskowitzCFlasterEDouble-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollisNeurology1990408121312182199847
   PubMed Web of Science ®Google Scholar
• TruongDDuaneDDJankovicJEfficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled studyMov Disord200520778379115736159
   PubMed Web of Science ®Google Scholar
• DresslerDTacikPAdib SaberiFBotulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®)J Neural Transm (Vienna)20141211293123913131
   PubMed Web of Science ®Google Scholar
• SethiKDRodriguezROlayinkaBSatisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystoniaJ Med Econ201215341942322208596
   PubMedGoogle Scholar
• MarshWAMonroeDMBrinMFGallagherCJSystematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystoniaBMC Neurol2014149124767576
   PubMed Web of Science ®Google Scholar
• DresslerDTacikPSaberiFABotulinum toxin therapy of cervical dystonia: duration of therapeutic effectsJ Neural Transm2015122229730025052566
   PubMed Web of Science ®Google Scholar
• AllerganBotox® 100 U summary of product characteristics [updated March 30, 2015] Available from: http://www.medicines.org.uk/EMC/medicine/112/SPC/Accessed December 18, 2015
   Google Scholar
• IpsenDysport® 300 U and 500 U summary of product characteristics [updated eptember 16, 2015] Available from: http://www.medicines.org.uk/EMC/medicine/870/SPC/Accessed December 18, 2015
   Google Scholar
• Merz Pharma UK LtdXEOMIN® 100 U summary of product characteristics [updated June 30, 2014] Available from: http://www.medicines.org.uk/emc/medicine/20666Accessed December 18, 2015
   Google Scholar
• GreenePFahnSDiamondBDevelopment of resistance to botulinum toxin type A in patients with torticollisMov Disord1994922132178196686
   PubMed Web of Science ®Google Scholar
• AlbaneseAAbbruzzeseGDresslerDPractical guidance for CD management involving treatment of botulinum toxin: a consensus statementJ Neurol2015262102201221325877834
   PubMed Web of Science ®Google Scholar
• FernandezHHPaganFDanisiFXCiDaBLE Study GroupProspective study evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm: Interim results from the first 145 subjects with cervical dystoniaTremor Other Hyperkinet Mov (N Y)20133
   Google Scholar
• WerleRWTakedaSYZontaMBGuimaraesATTeiveHAThe physical, social and emotional aspects are the most affected in the quality of life of the patients with cervical dystoniaArq Neuropsiquiatr201472640541024964104
   PubMed Web of Science ®Google Scholar
• HallettMAlbaneseADresslerDEvidence-based review and assessment of botulinum neurotoxin for the treatment of movement disordersToxicon2013679411423380701
   PubMed Web of Science ®Google Scholar
• HefterHBeneckeRErbguthFJostWReichelGWisselJAn open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)BMJ Open201334
   Web of Science ®Google Scholar
• EvidenteVGFernandezHHLeDouxMSA randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystoniaJ Neural Transm (Vienna)2013120121699170723779062
   PubMed Web of Science ®Google Scholar
• EvidenteVGTruongDJankovicJComellaCLGrafeSHanschmannAIncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well toleratedJ Neurol Sci201434611612025186131
   PubMed Web of Science ®Google Scholar
• DresslerDPausSSeitzingerAGebhardtBKupschALong-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystoniaJ Neurol Neurosurg Psychiatry20138491014101923687362
   PubMed Web of Science ®Google Scholar